Company news
Viridian Therapeutics, Inc. (NASDAQ:VRDN) news
Every Viridian Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results
August 6, 2026
Raymond Douglas, MD, PhD, Is First in the Nation to Infuse Newly FDA-Approved Thyroid Eye Disease Treatment, LUMVOA ™ (veligrotug-vvze)
July 16, 2026
Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease
June 26, 2026
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stoc...
May 6, 2026
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
May 5, 2026
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
March 30, 2026
Bambusa Therapeutics Appoints Todd James Chief Financial Officer
March 19, 2026
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results
February 26, 2026
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 8, 2026
Viridian Therapeutics Prepares for Transformational 2026
January 6, 2026
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease
December 22, 2025
Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 5, 2025
Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroi...
November 3, 2025
Viridian Therapeutics Announces Proposed Underwritten Public Offering
October 21, 2025
Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock
October 21, 2025
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
October 20, 2025
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
September 15, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 6, 2025
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug an...
July 30, 2025
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 3, 2025
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
May 30, 2025
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Act...
May 20, 2025
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
May 7, 2025
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
May 6, 2025
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
April 7, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
January 8, 2025
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid...
December 16, 2024
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
December 13, 2024
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
November 12, 2024
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
September 11, 2024
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active...
September 10, 2024
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
September 10, 2024
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
September 9, 2024
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
August 8, 2024
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
July 25, 2024
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-t...
June 11, 2024
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
May 31, 2024
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
May 10, 2024
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
May 8, 2024
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
April 29, 2024
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 5, 2024
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
February 16, 2024
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
January 17, 2024
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
January 8, 2024
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
January 4, 2024
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcuta...
December 18, 2023
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023